Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 134Breast Neoplasms 91Neoplasms 8Breast Neoplasms, Male 6Neoplasm Metastasis 5Advanced Breast Cancer 4Salivary Gland Neoplasms 3Prostate Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Osteoporosis 2Leiomyoma 2Infertility 2Advanced Prostate Cancer 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Primary Ovarian Insufficiency 1Primary Dysautonomias 1Patients With T1-4 Advanced Prostate Cancer 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Osteitis Deformans 1Myofibroma 1Lymphatic Metastasis 1Kidney Diseases 1Inflammatory Breast Neoplasms 1Hypertension 1Hyperlipidemias 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hormone Sensitive Prostate Cancer × Goserelin × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡